Format

Send to

Choose Destination
Value Health Reg Issues. 2019 May 9;18:145-150. doi: 10.1016/j.vhri.2019.03.003. [Epub ahead of print]

Health Technology Assessment and Its Use in Drug Policy in Malaysia.

Author information

1
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia. Electronic address: aakmal@usm.my.
2
School of Pharmaceutical Sciences, Universiti Sains Malaysia, Malaysia; Pharmacy Practice & Development Division, Ministry of Health, Malaysia.
3
Pharmacy Practice & Development Division, Ministry of Health, Malaysia.
4
United Nations University - International Institute for Global Health, Universiti Kebangsaan Malaysia (UNU-IIGH,UKM), Cheras, Kuala Lumpur, Malaysia.

Abstract

OBJECTIVE:

To describe the process and role of health technology assessment (HTA) in the context of drug policy in Malaysia.

METHODS:

We summarized the HTA process through review of documents and reports available in the public domain combined with the authors' experience.

RESULTS:

Health technology assessment plays an integral part in prioritizing treatment in public health facilities in Malaysia, particularly for the Ministry of Health Medicines Formulary (MOHMF). The MOHMF is the reference list of drugs allowed to be prescribed in the Ministry of Health (MOH) facilities. There are 2 organizations within the MOH that conduct HTA as their core activities, namely the Malaysian Health Technology Assessment Section and the Formulary Management Branch of Pharmacy Practice & Development Division. The assessment of pharmaceuticals for the purpose of listing medicines into the MOHMF is under the purview of the Formulary Management Branch. The evidence-based assessment focuses on safety, efficacy, effectiveness, and budget impact of the drug. Cost-effectiveness evidence is currently not mandatory but is of interest to the decision makers. The assessment outcomes are considered by the MOH Medicines List Review Panel for formulary decisions.

CONCLUSIONS:

Health technology assessment has supported formulary decisions in MOH. Evidence generation needs to progress beyond efficacy or effectiveness, safety, and budget impact to incorporate cost-effectiveness. Nevertheless, there are challenges to be met to achieve this. The impact of the HTA process is currently unknown and is yet to be evaluated formally.

KEYWORDS:

Malaysia; drug pricing; formulary listing; health technology assessment

PMID:
31082794
DOI:
10.1016/j.vhri.2019.03.003

Supplemental Content

Loading ...
Support Center